Business
AI deal signed with CytoReason
AI deal signed with CytoReason.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8311F\n Poolbeg Pharma PLC\n 24 March 2022\n \n \n \n \n Poolbeg Pharma plc\n \n \n \n \n \n Artificial Intelligence deal signed with CytoReason \n \n \n \n \n \n First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza\n \n \n Use of AI will help identify more targets, quicker and more cost effectively than previously possible\n \n \n \n \n \n 24 March 2022 - \n \n Poolbeg Pharma\n \n (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, \n has signed a deal with \n \n CytoReason\n \n , a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg's influenza disease progression data derived from human challenge study samples. \n \n \n \n \n \n The partnership will harness the insights of Poolbeg's unique repository of influenza human challenge trial* data and is another significant milestone in its strategy to leverage its proprietary databank to identify new pharmaceutical assets using artificial intelligence. CytoReason has built world-class validated AI models which can extrapolate immune cell behaviour based on bulk transcriptomics, making it an ideal partner to maximise the insights of Poolbeg's influenza data. \n To date, five of the world's top ten pharma companies use CytoReason's technology including Pfizer, Sanofi, Merck KGaA and Roche. Poolbeg's ability to execute a deal of this nature with a company of CytoReason's stature is a testament to the quality of Poolbeg's proprietary databank which will significantly improve the outputs of the collaboration.\n \n \n \n \n \n The partnership will bring Poolbeg's unique repository of clinical samples and associated data from influenza human challenge trials together with CytoReason's leading and validated AI technology. This will enable a deep understanding of the mechanism of influenza infection and recovery and, as a result, help identify novel drug targets for the disease. Poolbeg's datasets for influenza are already tailored for incorporation into CytoReason's platform algorithms. Both CytoReason and the Company are excited about the unique and novel disease-relevan...